The 2 biggest punchlines of an SGO Meeting in my career. Wish I could have been there in person, but what matters is a new SOC for our patients. Kudos #SGO #ENGOT #SGOMtg #GOG & investigators, patients & their families #PatientsPurposeProgress

Hard to conceive of a world in which the regulatory authority of the FDA could be undermined by a Judicial Branch created by Article III of the Constitution with zero discretion to answer any scientific question, and with no knowledge base whatsoever to allow them to do so.

Interesting. >1/20 endometrioid histology uterine cancers her2+, and have worse prognosis. Another potential targeted therapy opportunity. HER2 endometrioid endometrial cancer possesses distinct molecular and... sciencedirect.com/science/articl…

Release the Kraken!!!

Wow-HR of 0.67 for OVERALL survival in this challenging platinum-resistant setting. Great news for our patients=a 33% reduction in risk of death from ovarian cancer vs paclitaxel or pegylated liposomal doxorubicin or topotecan. investor.immunogen.com/news-releases/…

Critical to raise awareness this June Re the 4th most common cancer in women. 38,300 cases in U.S. when I finished training in 2001. 66,200 projected this year. And likely to surpass ovarian cancer deaths in 2024. prnewswire.com/news-releases/…

Continued progress in the “de-radicalization” of vulvar and cervical cancer surgical extirpation. Congrats to the investigators. Meets the “moves the needle” criterion.

Finally some local coverage from our hometown media illuminating the challenges we’re facing with our patients in Washington state. Cancer drug shortages lead to heart-wrenching decisions at WA hospitals seattletimes.com/seattle-news/h…

Thank you again Binay Shah, MD, MHA for allowing me to be a small part of the educational arm that drives the mission of the Binaytara Foundation. And thanks to Julie Graff for putting a fantastic program together. #BestofASCO #Portland #Oncology #CME

Please consider running (or walking) at the 30th Annual premier summer event to raise money for #ovariancancer research! Rivkin Center summerun.rivkin.org

And the sun sets on yet another remarkable year for our patients- with incorporation of immunotherapy in endometrial cancer and increased utilization of ADCs in cervical cancer and ovarian cancer. Happy New Year and cheers to further progress in 2024!

Editorial: “Reduced-Dose HPV Vaccination — Implications for Cancer Prevention Policy” by Leeya F. Pinder, MD, MPH eviden.cc/3U9py0c #Oncology

Excited to be a part of yet another Binaytara Foundation program furthering the mission of Dr. & Mrs. Shah and seeing colleagues and friends at the Alaska Hematology Oncology Conference. And of course seeing beautiful Anchorage again.

What a kickoff to #endometrialcancer awareness month @ #ASCO24 by Dr. Makker with this outstanding data from SIENDO study update: mPFS w/ Selinexor maintenance in TP53wt/pMMR 39.5 mo vs 4.9 mo w/ placebo with HR 0.36-clearly standard of care changing in this pMMR/TP53wt subgroup.

Wow yet another immunotherapeutic option for what will soon be the 3rd most common cancer in U.S. women. The tidal wave of checkpoint inhibitors for Gyn Ca is coming! targetedonc.com/view/durvaluma…

FWC Move 4 Her 2024 : Make a donation today to support FWC Move 4 Her 2024 2024-move4her.raiselysite.com/dan-veljovich #fwc-move-4-her-2022 via Raisely

Exciting and beautiful day @ #nwhopeandhealing #LifeinColor brunch/auction celebrating breast and gynecologic cancer survivors. Inspired by and in awe of these women, and glad to be involved! e.givesmart.com/events/BEt/

A great cause if you are interested: nwhopeandhealing.org